Iovance Biotherapeutics

Iovance Biotherapeutics is a United States biopharmaceutical company headquartered in San Carlos, California. Its research and commercial focus is tumor-infiltrating lymphocyte (TIL) therapy, a form of adoptive cell therapy that uses a patient's own immune cells to recognize and attack cancer. Rather than developing conventional small-molecule drugs or antibodies alone, Iovance works to isolate lymphocytes that have naturally migrated into a patient's tumor, expand those cells outside the body, and return them to the patient as an individualized cellular treatment. The company was established in 2007 under the name Genesis Biopharma. In 2013, Genesis Biopharma merged with Lion Biotechnologies, after which the combined business operated as Lion Bio Pharma. The company adopted the Iovance Biotherapeutics name in 2017, reflecting its more focused identity as a developer of cell therapies for cancer. Its corporate evolution accompanied a broader effort to translate academic and clinical work on TILs into a scalable treatment platform. Iovance's principal commercial product is lifileucel, marketed in the United States as Amtagvi. In February 2024, the U.S. Food and Drug Administration granted accelerated approval to Amtagvi for adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking antibody and, when appropriate, a BRAF inhibitor with or without a MEK inhibitor. The approval made Amtagvi the first individualized TIL therapy authorized by the FDA and established Iovance as a commercial oncology-cell-therapy company. The treatment is manufactured from a patient's tumor tissue: tumor-resident lymphocytes are collected, expanded, and administered following a preparative lymphodepletion regimen, generally with interleukin-2 support after infusion. The company's development strategy extends beyond melanoma. Iovance has investigated TIL monotherapy and combination regimens in several advanced solid tumors, including non-small-cell lung cancer and sarcoma. Research programs have also examined combinations with immune-checkpoint inhibitors and other treatment approaches intended to improve the activity or applicability of TIL therapy. These programs are designed to test whether the platform can serve patients whose cancers have progressed after established therapies. TIL treatment presents distinctive manufacturing and operational challenges because each product is made for an individual patient. Iovance's business therefore depends not only on clinical efficacy but also on the ability to coordinate tumor collection, cell processing, quality control, logistics, treatment-center preparation, and patient scheduling. The company's positioning combines advanced oncology research with a manufacturing infrastructure intended to make personalized cellular therapy available through a broader network of treatment centers. Iovance remains an active biopharmaceutical company centered on oncology cell therapy. Amtagvi is its principal approved offering, while additional TIL-based indications and combination therapies remain dependent on clinical evidence, regulatory review, and manufacturing execution. The company is best understood as a specialized cancer-immunotherapy developer rather than a diversified pharmaceutical group.

Iovance Biotherapeutics traces its corporate history to Genesis Biopharma, which was founded in 2007 in the United States. The early company operated in the biotechnology field and later became associated with the development of tumor-infiltrating lymphocyte therapies, an approach in which immune cells recovered from a patient's tumor are expanded in the laboratory and reinfused as a cancer treatment. A significant corporate transition occurred in 2013, when Genesis Biopharma merged with Lion Biotechnologies. Following the transaction, the combined company used the name Lion Bio Pharma. The merger formed the corporate basis for the business that would later become Iovance and supported a more concentrated focus on cellular immunotherapy and TIL development. In 2017, Lion Bio Pharma was rebranded as Iovance Biotherapeutics. The new name accompanied the company's effort to establish a distinct identity around the development of individualized cell therapies for cancer. Its research and clinical programs were directed toward advanced solid tumors, an area in which many cell-therapy approaches had historically faced challenges involving tumor access, immune suppression, manufacturing complexity, and limited persistence of therapeutic cells. Iovance's central platform involves harvesting lymphocytes that have infiltrated a patient's tumor, expanding those cells outside the body, and returning them to the same patient after preparative treatment. This personalized process differs from off-the-shelf medicines because the therapeutic product is linked to an individual tumor sample and requires coordinated manufacturing and clinical delivery. The platform's potential value lies in using naturally tumor-reactive immune cells while producing them in quantities intended to support treatment. The company's leading clinical program became lifileucel, later branded Amtagvi. Clinical development focused initially on patients with advanced melanoma who had already received established immune-checkpoint therapy and, where applicable, targeted treatment directed at BRAF and MEK pathways. In February 2024, the FDA granted accelerated approval to Amtagvi for an indicated population of adults with unresectable or metastatic melanoma after specified prior treatments. The authorization represented a major regulatory milestone for Iovance and made Amtagvi the first individualized TIL therapy approved by the FDA. The accelerated approval also moved Iovance from a development-stage biotechnology company toward commercial operations. Commercializing a personalized TIL product requires more than regulatory authorization: patients need tumor-resection procedures, manufacturing capacity, release testing, treatment-center coordination, lymphodepletion, and post-infusion management. These requirements make supply-chain reliability and treatment-site readiness important parts of the company's operating model. Alongside the melanoma program, Iovance has investigated TIL monotherapy and combination therapies in other advanced solid tumors. Its clinical work has included non-small-cell lung cancer and sarcoma, as well as studies combining TIL therapy with other anticancer agents. These programs seek to determine whether the company's platform can be applied across a wider range of tumors and whether combinations can improve response rates or durability. Iovance's history therefore consists of three connected phases: formation as Genesis Biopharma, corporate consolidation and operation as Lion Bio Pharma, and reorientation under the Iovance name toward TIL-based cancer immunotherapy. The 2024 approval of Amtagvi marked the most consequential turning point, establishing the company as an active commercial cell-therapy business while leaving further growth dependent on clinical expansion, regulatory outcomes, and the practical execution of individualized manufacturing.

• 2024

  FDA accelerated approval of Amtagvi

  [1]Iovance Biotherapeuticsen.wikipedia.org

  The FDA grants accelerated approval to lifileucel, marketed as Amtagvi, for certain previously treated adults with unresectable or metastatic melanoma.

• 2017

  Company adopts the Iovance name

  [1]Iovance Biotherapeuticsen.wikipedia.org

  Lion Bio Pharma is rebranded as Iovance Biotherapeutics, aligning the corporate identity with its cell-therapy development strategy.

• 2013

  Merger with Lion Biotechnologies

  [1]Iovance Biotherapeuticsen.wikipedia.org

  Genesis Biopharma merges with Lion Biotechnologies and subsequently operates as Lion Bio Pharma.

• 2007

  Genesis Biopharma is founded

  [1]Iovance Biotherapeuticsen.wikipedia.org

  The company that would eventually become Iovance Biotherapeutics is established as Genesis Biopharma.

A specialist oncology company focused on commercializing and expanding personalized tumor-infiltrating lymphocyte therapy for advanced solid tumors.

• Personalized tumor-infiltrating lymphocyte therapy · 2024

  Amtagvi

  Amtagvi is the commercial brand name for lifileucel, an autologous TIL therapy developed by Iovance. The product is made using lymphocytes obtained from a patient's tumor, expanded in a controlled manufacturing process, and then returned to that patient after preparative lymphodepletion. In 2024, the FDA granted accelerated approval for certain adults with unresectable or metastatic melanoma whose disease had progressed after specified prior therapies. Its individualized production process makes treatment-center coordination and manufacturing logistics central to delivery.

• Investigational cancer cell therapy

  TIL monotherapy programs

  Iovance has investigated tumor-infiltrating lymphocyte therapy as a standalone treatment in advanced solid tumors beyond the initial melanoma indication. These programs seek to establish whether expanded, tumor-derived immune cells can produce clinically meaningful responses in cancers with limited options after standard therapies. The programs have included research in diseases such as non-small-cell lung cancer and sarcoma, with outcomes dependent on clinical-trial data and regulatory review.

• Investigational combination immunotherapy

  TIL combination therapies

  Iovance has studied TIL therapy in combination with other anticancer treatments, including immune-checkpoint approaches. Combination development is intended to address the biology of advanced solid tumors and potentially improve immune-cell activity, persistence, or response durability. These programs remain part of the company's clinical-development portfolio rather than established commercial products.

• 2024

  Commercial introduction of AmtagviProduct launch

  Background

  The FDA granted accelerated approval to lifileucel for a defined population of adults with unresectable or metastatic melanoma after specified prior treatments.

  Action taken

  Iovance began the transition from a clinical-stage developer to a commercial oncology cell-therapy company under the Amtagvi brand.

  Aftermath

  The approval established Amtagvi as the company's lead commercial offering while additional TIL indications and combinations remained under clinical investigation.

  Source

• 2017

  Rebrand as Iovance BiotherapeuticsStrategy

  Background

  Following its earlier Genesis Biopharma and Lion Bio Pharma identities, the company sought a clearer corporate position around tumor-infiltrating lymphocyte and cancer-cell-therapy development.

  Action taken

  The company adopted the Iovance Biotherapeutics name and continued its focus on TIL-based oncology programs.

  Aftermath

  The rebrand created the identity under which the company later advanced lifileucel and other TIL programs.

  Source

1. 1Iovance Biotherapeuticsen.wikipedia.org
2. 2Iovance Biotherapeutics official websiteiovance.com